Replies to post #5292 on Dendreon Corp fka DNDNQ

[walldiver]

I don't think David believes GVAX will fail the first interim look. That was me who posted that. CEGE powered the trial assuming the 18.9 month median survival for Taxotere without taking into account the asymptomatic subgroup's MS.